Science and Research

Tailoring lipid nanoparticles for T-cell targeting in allergic Asthma: Insights into efficacy and specificity

Asthma impacts over 300 million patients globally, with significant health implications, especially in cases of its allergic subtype. The disease is characterized by a complex interplay of airway inflammation and immune responses, often mediated by T(H)2 cell-related cytokines. In this study, we engineered lipid nanoparticles (LNPs) to specifically deliver therapeutic siRNA via the transferrin receptor to T cells. Strain-promoted azide-alkyne cycloaddition (SPAAC) was employed for the conjugation of transferrin ligands to PEGylated lipids in the LNPs, with the goal of enhancing cellular uptake and gene knockdown. The obtained LNPs exhibited characteristics that make them suitable for pulmonary delivery. Using methods such as nanoparticle tracking analysis (NTA) and enzyme-linked immunosorbent assay (ELISA), we determined the average number of transferrin molecules bound to individual LNPs. Additionally, we found that cellular uptake was ligand-dependent, achieving a GATA3 knockdown of more than 50% in relevant in vitro and ex vivo models. Notably, our findings highlight the limitations inherent to modifying the surface of LNPs, particularly with regard to their targeting capabilities. This work paves the way for future research aimed at optimizing targeted LNPs for the treatment of immunologic diseases such as allergic asthma.

  • Jürgens, D. C.
  • Müller, J. T.
  • Nguyen, A.
  • Merkel, O. M.
Publication details
DOI: 10.1016/j.ejpb.2024.114242
Journal: Eur J Pharm Biopharm
Pages: 114242 
Work Type: Original
Location: CPC-M
Disease Area: AA
Partner / Member: LMU
Access-Number: 38442794

DZL Engagements

chevron-down